LOUISVILLE, Colo., Jan. 12 /PRNewswire/ -- RxKinetix, Inc., a specialty pharmaceutical company developing new therapeutics focused in oncology care, today announced that the Company has been awarded the Life Sciences Company of the Year Award by the University of Colorado Technology Transfer Office.
RxKinetix holds license to two technologies from the University License Equity Holdings, Inc. relating to drug delivery. The Company recently completed a successful Phase 2 clinical trial for its lead product, RK-0202 for treatment of oral mucositis in head and neck cancer patients. "We are honored to receive this award from the University of Colorado Technology Transfer Office. It is a wonderful endorsement of our on-going success and recognition of the excellent work of all the employees of RxKinetix," said Harry Ross M. D., chairman and CEO of RxKinetix.
"RxKinetix' successful Phase 2 clinical trial for RK-0202 made it an obvious choice for this award. It is always gratifying to see success from a company founded on technology from the University of Colorado," said David Allen, Associate Vice President for Technology Transfer, University of Colorado.
RxKinetix, Inc. is a specialty pharmaceutical company developing new therapeutics focused in oncology care. Using proven pharmaceuticals and proprietary polymer-based drug delivery technologies, RxKinetix creates new drugs or enhances existing drugs. The Company's strategy improves timelines and reduces risk during clinical development. RxKinetix has a strong intellectual property portfolio in support of its products and technologies. More information regarding RxKinetix is available at www.rxkinetix.com.
CONTACT: Joanna Money, Ph.D., Vice President, Corporate Development ofRxKinetix, Inc., +1-303-926-1900, email@example.com